Pretreatment absolute monocyte count is a novel biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Paper No: 98
| Oncology - Bladder and Upper Urinary Tract Urothelial Cancer
Koichiro Ogihara
3-Minute Oral Presentation 2 | Oncology (Bladder & UTUC) 2
08 Aug 2019 |
11:30:00-12:30:00